期刊
FRONTIERS IN GENETICS
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2022.885635
关键词
epigenetics; cancer; DNA methylation; histone modification; chromatin remodelling; cancer therapies
资金
- Indian Council of Medical Research (ICMR), New Delhi, India
- [3/2/3/21/2020/NCD-III]
The global cancer cases and mortality rates are increasing, and efficient biomarkers are needed for accurate screening and diagnosis. Alterations in epigenetic marks may serve as potential biomarkers for early cancer detection. This review discusses the key epigenetic mechanisms and their deregulation in cancer etiology, exploring the future prospects of cancer precision medicine.
The global cancer cases and mortality rates are increasing and demand efficient biomarkers for accurate screening, detection, diagnosis, and prognosis. Recent studies have demonstrated that variations in epigenetic mechanisms like aberrant promoter methylation, altered histone modification and mutations in ATP-dependent chromatin remodelling complexes play an important role in the development of carcinogenic events. However, the influence of other epigenetic alterations in various cancers was confirmed with evolving research and the emergence of high throughput technologies. Therefore, alterations in epigenetic marks may have clinical utility as potential biomarkers for early cancer detection and diagnosis. In this review, an outline of the key epigenetic mechanism(s), and their deregulation in cancer etiology have been discussed to decipher the future prospects in cancer therapeutics including precision medicine. Also, this review attempts to highlight the gaps in epigenetic drug development with emphasis on integrative analysis of epigenetic biomarkers to establish minimally non-invasive biomarkers with clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据